{"disease":{"id":"protein","name":"protein"},"drugs":{"marketed":[{"drug_id":"atorvastatin","indication_name":"Familial type 3 hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"lorlatinib-with-chemotherapy-2","indication_name":"ALK-positive metastatic NSCLC with brain metastases and with or without echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorlatinib with chemotherapy 2","generic_name":"lorlatinib-with-chemotherapy-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK","drug_class":"ALK inhibitor","quality_score":40,"revenue":"798","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Megakaryocyte Erythroid Potent Protocadherin-related Protein (MEPEP) associated Hemophagocytic Lymphohistiocytosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"hydrocortisone-succinate","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"telisotuzumab","indication_name":"non-small cell lung cancer (NSCLC) with high c-Met protein overexpression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emrelis","generic_name":"TELISOTUZUMAB","company_name":"Abbvie Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Emrelis binds to the c-Met protein on cancer cells, blocking its growth-promoting signals."},{"drug_id":"telisotuzumab","indication_name":"locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emrelis","generic_name":"TELISOTUZUMAB","company_name":"Abbvie Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Emrelis binds to the c-Met protein on cancer cells, blocking its growth-promoting signals."},{"drug_id":"betamethasone-acetate","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"simvastatin","indication_name":"Familial type 3 hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"simvastatin","indication_name":"Hypoalphalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolone","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"acipimox","indication_name":"Hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Olbemox","generic_name":"ACIPIMOX","company_name":"","drug_phase":"phase_3","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"acipimox","quality_score":null,"revenue":null,"mechanism":"Olbemox works by activating the hydroxycarboxylic acid receptor 2, which helps to reduce the production of triglycerides in the liver."},{"drug_id":"hydrocortisone","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"myoinositol","indication_name":"Hypoalphalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Myoinositol","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"fenofibrate","indication_name":"Hypoalphalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tricor (Micronized)","generic_name":"FENOFIBRATE","company_name":"Salix","drug_phase":"marketed","molecular_target":"PPARα","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion."},{"drug_id":"rosuvastatin","indication_name":"Familial type 3 hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"lipitor","indication_name":"Familial type 3 hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"methylprednisolone-acetate","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Medrol","generic_name":"METHYLPREDNISOLONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Depo-Medrol works by binding to the glucocorticoid receptor, which then regulates the expression of genes involved in inflammation and immune response."},{"drug_id":"alipogene-tiparvovec","indication_name":"Familial lipoprotein lipase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glybera","generic_name":"ALIPOGENE TIPARVOVEC","company_name":"uniQure biopharma B.V.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"choline-fenofibrate","indication_name":"Hypoalphalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trilipix","generic_name":"CHOLINE FENOFIBRATE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Fatty acid-binding protein, intestinal","drug_class":"Peroxisome Proliferator Receptor alpha Agonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"betamethasone","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"lovastatin","indication_name":"Hypoalphalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"cortisol","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolon","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Transfusion reaction due to serum protein reaction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"olbetam","indication_name":"Hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olbetam","company_name":"University of Aarhus","drug_phase":"phase_1","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":4,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1496","indication_name":"Treat primary dysbetalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ROSUVASTATIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"caduet","indication_name":"Primary Dysbetalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"inositol","indication_name":"Hypoalphalipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inosital","generic_name":"INOSITOL","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"inositol","quality_score":null,"revenue":null,"mechanism":"Inosital works by influencing the metabolism of lipids in the body."}],"pipeline":[{"drug_id":"odsh-at-0-125-mg-kg-h","indication_name":"Protein-Losing Enteropathy Secondary to Single Ventricle","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ODSH at 0.125 mg/kg/h","company_name":"Jazz Pharmaceuticals","drug_phase":"discontinued","molecular_target":"Intestinal lymphatic proteins (albumin, immunoglobulins); mechanism targets protein loss pathway in enteropathy","drug_class":"Protein sequestrant; modified polysaccharide; orphan therapeutic","quality_score":null,"revenue":null,"mechanism":"ODSH is a modified chitosan polymer that binds intestinal lymphatic proteins to reduce protein loss in enteropathy."}],"offLabel":[],"totalMarketed":35,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT06339229","title":"Postoperative New-onset Proteinuria and Adverse Outcomes.","phase":"","overall_status":"COMPLETED","enrollment_count":2983899,"lead_sponsor_name":"Yaozhong Kong","has_results":false},{"nct_id":"NCT03887520","title":"Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)","phase":"NA","overall_status":"COMPLETED","enrollment_count":49001,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05154370","title":"China National Registry of Neuro-Inflammatory Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT06750965","title":"Multi-center Screening for Serum M Protein","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT06082284","title":"A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT04023552","title":"Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8323,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01231945","title":"Low-Cost Molecular Cervical Cancer Screening Study","phase":"","overall_status":"COMPLETED","enrollment_count":7500,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06443333","title":"National, Multicentric Registry Study on Neuroimmunological Diseases in China","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT02849977","title":"Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers","phase":"","overall_status":"COMPLETED","enrollment_count":5966,"lead_sponsor_name":"Rhythm Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07517263","title":"An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":5700,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03683667","title":"Protein Plus: Improving Infant Growth Through Diet and Enteric Health","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":5283,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT05801263","title":"ctDNA Methylation for Epithelial Ovarian Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT05081440","title":"A Multi-center, Prospective, Observational Study to Describe the siTuation of Blood Lipid mAnagement Among the Population With hypeRtension and/or Type 2 diabeTes in Community Health Center","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT06767722","title":"Effectiveness of a Lifestyle Intervention for Pregnant Women With Abnormal Glucose Metabolism in Early Pregnancy: EAGM Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":3430,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06014060","title":"24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":3300,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT06115122","title":"PEPPI Study: Identification of Women at Risk for Placental Dysfunction","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Oulu University Hospital","has_results":false},{"nct_id":"NCT06690593","title":"Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy","phase":"","overall_status":"RECRUITING","enrollment_count":2990,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT06304415","title":"Elevated Lipoprotein(a) in Hospital Staff","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2800,"lead_sponsor_name":"Changi General Hospital","has_results":false},{"nct_id":"NCT07298668","title":"Cardiovascular Risk Factors in Middle Eastern Patients With Stroke","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Jordan Collaborating Cardiology Group","has_results":false},{"nct_id":"NCT06087835","title":"Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1835,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03110432","title":"Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry","phase":"","overall_status":"COMPLETED","enrollment_count":1695,"lead_sponsor_name":"GWT-TUD GmbH","has_results":false},{"nct_id":"NCT07333196","title":"Tongji NADs Cohort","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1550,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT03900221","title":"French Registry for Monitoring Pregnancies for Multiple Sclerosis","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03510286","title":"Validation of a PrCr Dipstick Diagnostic Test in Ghana","phase":"","overall_status":"COMPLETED","enrollment_count":1483,"lead_sponsor_name":"PATH","has_results":false},{"nct_id":"NCT02798042","title":"Does the Presence of Preoperative Proteinuria Predict Postoperative Acute Kidney Injury in Obese Patients Undergoing Elective Laparoscopic Surgery?","phase":"","overall_status":"COMPLETED","enrollment_count":1434,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT05801276","title":"ctDNA Methylation for Detecting Ovarian Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":1400,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT05439174","title":"Impact of IDPN on Nutrition Markers in Patients Receiving ICHD","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Patient Care America","has_results":false},{"nct_id":"NCT04128475","title":"Observational Study of Cardiovascular Disease.","phase":"","overall_status":"TERMINATED","enrollment_count":1137,"lead_sponsor_name":"University of Sydney","has_results":false},{"nct_id":"NCT05893446","title":"Essential Connections: Hospital to Community Impacting Malnutrition Outcomes in Older Adults","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1120,"lead_sponsor_name":"Academy of Nutrition and Dietetics","has_results":false},{"nct_id":"NCT05870657","title":"Adherence and Persistence to Inclisiran Among Early Users in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":1109,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT00001168","title":"Evaluation of Lipoproteins","phase":"","overall_status":"COMPLETED","enrollment_count":1017,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT03528031","title":"Habitual Diet and Avocado Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":1008,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false},{"nct_id":"NCT05204459","title":"MS-ResearchBiomarkerS","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT04299529","title":"Urinary Proteomics Combined With Home Blood Pressure Telemonitoring for Health Care Reform","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"KU Leuven","has_results":false},{"nct_id":"NCT05745272","title":"Cardiovascular Risk Categories and Attaining LDL-C Targets in Middle Eastern Adults Aged 30-55 Years of Age","phase":"","overall_status":"TERMINATED","enrollment_count":1000,"lead_sponsor_name":"Jordan Collaborating Cardiology Group","has_results":false},{"nct_id":"NCT00033137","title":"Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":950,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03549637","title":"Prevalence of fAmilial hypobetalipopRoTeinemIa in psychiaTrIc pOpulatioN (PARTITION)","phase":"NA","overall_status":"COMPLETED","enrollment_count":896,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT04807400","title":"Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":892,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03417531","title":"Sarcopenia Prevention With a Targeted Exercise and Protein Supplementation Program","phase":"NA","overall_status":"COMPLETED","enrollment_count":801,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT04431024","title":"Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04150315","title":"Arterial Composition and Cardiovascular Outcome in DIabeteS","phase":"","overall_status":"UNKNOWN","enrollment_count":763,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT00001154","title":"Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins","phase":"","overall_status":"COMPLETED","enrollment_count":759,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT00552097","title":"Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":720,"lead_sponsor_name":"Organon and Co","has_results":false},{"nct_id":"NCT04393909","title":"Improving Safety of Diagnosis and Therapy in the Inpatient Setting","phase":"NA","overall_status":"COMPLETED","enrollment_count":700,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT07202494","title":"Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT04804618","title":"Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease","phase":"","overall_status":"RECRUITING","enrollment_count":650,"lead_sponsor_name":"Guangzhou University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT05976893","title":"Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":620,"lead_sponsor_name":"Xiang Xie","has_results":false},{"nct_id":"NCT06596746","title":"Neurodegenerative Diseases Progression Markers (MARKERS-NDD)","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Casa di Cura San Raffaele Cassino","has_results":false},{"nct_id":"NCT06331260","title":"Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Zhejiang University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}